$MJNA Announces Its Cannabis Drug Research Update

Medical Marijuana, Inc. is placing its investment resources toward research and development of drugs derived from cannabis for distribution as pharmaceutical products. The collective results have the potential to impact hundreds of millions of lives around the world. One groundbreaking cannabis-derived medical product to enter clinical trials conducted by investment portfolio company AXIM® may be on the market as soon as 2017, according to a recent report by Reuters.

MJNA’s Investment in Kannalife Helps Advance Research in Cannabinoid Based Therapeutics

Kannalife™, an MJNA investment company, currently holds two licenses with National Institutes of Health for U.S. Patent 6,630,507 “Cannabinoids as Antioxidants and Neuroprotectants.” These licenses are currently in use by Kannalife™ to develop novel therapeutic drugs to treat chronic traumatic encephalopathy (CTE) and hepatic encephalopathy (HE).

Kannalife’s scientific team has researched the effects of cannabidiol (CBD) on non-differentiated native neuronal cells and has determined cannabidiol’s potential as a target drug candidate to treat oxidative stress-related disorders, CBD’s therapeutic index, and CBD’s limitations in pharmaceutical target drug design.

In tandem with its findings on CBD, Kannalife™ has developed a new cannabidiol-like molecule called KLS-13019 that, through pre-clinical testing and pharmacokinetic (PK) studies, indicates improvement over CBD’s role as a neuroprotectant through increased potency, as well as potential for greater safety through reduced toxicity. Side-by-side comparisons between CBD and KLS-13019 have also shown that KLS-13019 has marked improvements over CBD in oral bioavailability, CNS penetration, blood-plasma concentrations, and cognitive improvement in murine behavioral models.

The abstract, as well as the purchase of the full version of the publication on the Discovery of KLS-13019 is available online at:https://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.6b00009.

Medical Marijuana, Inc. provided $1.5 million in Series A funding to Kannalife Sciences, Inc. in March of 2013. In addition, MJNA owns 16.4 percent of Kannalife Sciences, Inc.

MJNA Funds New Medicine Delivery Methods

In May 2015, MJNA’s joint venture, CanChew® Biotechnologies, LLC (CanChew®) was issued the world’s first patent on cannabinoid controlled-release chewing gum. The exclusive agreement to bring a new medical product, MedChew RX™, to market is held by AXIM® Biotechnologies, Inc. (AXIM), an MJNA investment. AXIM® holds additional intellectual property (IP) that will innovate the way that cannabis-based medicines are manufactured from seed to product and taken by patients worldwide.

MedChew RX™ is on schedule to begin clinical trials in The Netherlands for pain and spasticity for Multiple Sclerosis (MS). According to a global news report by Reuters, AXIM® may be able to bring MedChew RX™ to market as both a ground-breaking new cannabinoid (THC/CBD) controlled-release chewing gum and new patented medicine delivery method as early as 2017.

The mission of AXIM® is to develop solutions for conditions that have no known cure; presently there are 15 conditions identified including: MS, spasticity, pain, Parkinson disease, Alzheimer’s disease/dementia, ADHD (attention deficit hyperactivity disorder), psychosis, PTSD, autism, RLS (restless leg syndrome), glaucoma, IBD, IBS, andCrohn’s disease.

AXIM® Biotech is a significant investment company for Medical Marijuana, Inc.. MJNA Investment Holdings, LLC holds 14,943,650 shares of common stock and 500,000 shares of preferred stock in the cutting-edge biotechnology innovator.

MJNA Empowers Global Cannabis Healthcare Reform

While cannabis remains illegal in Brazil and hemp not legal to grow, a landmark decision by a Federal Judge in 2014 approved the import of MJNA’s CBD hemp oil product, RSHO™, for a Brazilian child, Anny Fischer, deeming it “inhumane” to keep it from her. Afterward, the Brazilian government expanded its approval to include any individual with a medical recommendation and authorization to import under the indication of Refractory Epilepsy. The program has gone so well, that ANVISA then authorized two additional indications: Parkinson’s disease, and chronic pain, including migraine headache. Additional indications are expected in the months ahead.